Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Belmont, Massachusetts 02478


Purpose:

Bipolar disorder is a common and often chronic and debilitating mental illness. The depressive phase of bipolar disorder contributes the largest portion of the disorder, and treatment resistant bipolar depression represents a significant public health problem. Recent research has suggested that bipolar depression is associated with elevated brain glutamate activity. We hypothesize that riluzole, a drug approved for ALS which inhibits glutamate activity, will lead to clinical improvement in patients with bipolar depression.


Study summary:

We hypothesize that riluzole will lead to significant reduction in depressive symptoms as measured by the Hamilton Depression Rating Scale (HAM-D). Additionally, improvement in depressive symptoms will be associated with reduced glutamate levels in the anterior cingulate cortex, but not parieto-occipital cortex, both at day two and day 42.


Criteria:

Inclusion Criteria: - Male or female age 18-65 - Meets DSM-IV criteria for Bipolar Disorder and is currently depressed - Current score of >/= 18 on the Hamilton Depression Scale Exclusion Criteria: - Active psychotic/manic symptoms - Lifetime history of schizophrenia or obsessive compulsive disorder - Clinically significant medical disease - Women who are pregnant or lactating and women who are not using a medically accepted method of contraception.


NCT ID:

NCT00544544


Primary Contact:

Principal Investigator
Dost Ongur, M.D, Ph.D.
Mclean Hospital


Backup Contact:

N/A


Location Contact:

Belmont, Massachusetts 02478
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.